Company Overview - Wante Bio (603392) closed at 54.66 yuan as of August 15, 2025, down 3.0% from last week's 56.35 yuan [1] - The stock reached a high of 57.1 yuan and a low of 54.24 yuan during the week, hitting its lowest point in nearly a year [1] - The current market capitalization is 69.152 billion yuan, ranking 1st in the bioproducts sector and 223rd among all A-shares [1] Recent Developments - Wante Bio announced the use of 550 million yuan of idle raised funds for cash management, approved by the sixth board and supervisory meetings [1] - The maximum amount for investment in principal-protected products is capped at 1.5 billion yuan, with individual product terms not exceeding 12 months [1] - The total raised funds amount to approximately 3.5 billion yuan, with net proceeds of about 3.46 billion yuan after deducting issuance costs [1] Investment Products - The company is investing in structured deposits, specifically "Juyin Exchange Rate - Linked to Euro to US Dollar Exchange Rate Interval Accumulated Structured Deposit" and "Juyin Exchange Rate - Linked to Euro to US Dollar Call Three-Element Structured Deposit" [1] - The investments are allocated as 200 million yuan and 350 million yuan respectively, with both products having a term of 364 days [1] - Expected annualized returns for these products range from 1.20% to 2.03% [1]

从山峰掉入谷底，万泰生物只用了三年。 万泰生物 （603392.SH）上市以来的首次亏损，出现在2025年。 近日万泰生物发布业绩预告，预计2025年半年度实现归属于母公司所有者的净利润为-16,000万元 到-13,000万元。 在2022年达到高峰后，万泰生物业绩就一直下滑。2023年其营业收入同比下降50.73%，归母净利润同 比下降73.65%。2024年业绩继续"腰斩"，但至少还能盈利，2025年则直接陷入亏损中。公司第一季度净 利润即亏损5277.69万元。 资钛认为，万泰生物业绩下滑，与其过去几年依靠单一业务和单一产品有很大关系。风靡一时的二价宫 颈癌 疫苗 上市头几年，着实拉高了公司业绩，但随着该产品销量下滑，万泰生物便到了如今的局面。 今年6月，万泰生物祭出另一大"杀器"——九价宫颈癌疫苗，并以499元/支的低价抢夺市场，但毕竟出 场太晚，它的表现如何，关系着万泰的命运。 2022年，万泰生物实现营业收入111.85亿元，实现净利润47.36亿元，这是公司上市以来业绩的最高水 平。那一年，万泰生物疫苗产品卖了84.93亿元，但成本只有5.19亿元，毛利率高达93.89%， 体外诊断 卖了26 ...